Ypsomed Competitors and Similar CompaniesClear all
 Ypsomed Ypsomed is a company that develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. |  GI Windows GI Windows is a clinical-stage medical device company specializing in non-surgical treatment of type-2 diabetes and obesity. |  U.S. NeuroSurgical U.S. NeuroSurgical is a medical services company that partners with hospitals and physicians to own and operate facilities utilizing state-of-the-art and innovative technologies in medical treatment and/or diagnosis. |  Tandem Diabetes Care Tandem Diabetes Care is a medical device company that engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. |  Cell MedX Cell MedX Corp. is an early development stage company focused on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. | |
Founding Date | Founding Date 2003 | Founding Date 2012 | Founding Date 1993 | Founding Date 2006 | Founding Date 2014 |
Type | Type Public | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Westwood, US HQ | Locations Rockville, US HQ | Locations San Diego, US HQ Markham, CA Schiphol, NL | Locations Carson City, US HQ | |
Employees | Employees 2,60013% increase | Employees 244% increase | Employees 3 | Employees 2,65010% increase | Employees 150% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 9.4 m | Valuation ($) 2.2 b | Valuation ($) 8.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) CHF748.9m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $1m (FY, 2025) | Revenue (est.) $1b (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods CHF351.1m (FY, 2025) | Cost of goods N/A | Cost of goods $906k (FY, 2025) | Cost of goods $468.7m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit CHF398.8m (FY, 2025) | Gross profit N/A | Gross profit $118k (FY, 2025) | Gross profit $546m (FY, 2025) | Gross profit N/A |
Net income | Net income CHF87.5m (FY, 2025) | Net income N/A | Net income ($7.8m) (FY, 2025) | Net income ($204.7m) (FY, 2025) | Net income ($566.3k) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 42.9m | Total funding raised N/A | Total funding raised $ 401.5m | Total funding raised N/A |
View Company Profiles
GI Windows is a clinical-stage medical device company specializing in non-surgical treatment of type-2 diabetes and obesity.
View companyU.S. NeuroSurgical is a medical services company that partners with hospitals and physicians to own and operate facilities utilizing state-of-the-art and innovative technologies in medical treatment and/or diagnosis.
View companyTandem Diabetes Care is a medical device company that engages in the design, development, and commercialization of products for people with insulin-dependent diabetes.
View companyCell MedX Corp. is an early development stage company focused on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications.
View company